Document Detail


Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study.
MedLine Citation:
PMID:  21639407     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Hypertension is a leading risk factor for development of heart failure, stroke and renal disease in the elderly.
OBJECTIVE: The objective of this study was to evaluate, by means of a prespecified secondary analysis of a 12-week, open-label, single-arm, dose-titration study, the blood pressure (BP)-lowering efficacy and safety of an olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)-based titration regimen in patients aged ≥65 years with hypertension. Subgroups were stratified by age (≥65 to ≤75 or >75 years), sex (male or female) and race (Black or non-Black).
METHODS: Following a 2- to 3-week placebo run-in phase, patients received OM 20 mg, uptitrated to OM 40 mg, followed by addition of HCTZ 12.5-25 mg step-wise at 3-week intervals if seated cuff BP (SeBP) was ≥120/70 mmHg. Patients below this target SeBP were maintained at their current dose but uptitrated to the next consecutive dose if mean seated cuff systolic BP (SBP) was ≥140 mmHg and/or mean seated cuff diastolic BP was ≥90 mmHg at follow-up visits. Efficacy was assessed by 24-hour ambulatory BP monitoring (ABPM) and SeBP measurements. The primary efficacy variable was the change from baseline in mean 24-hour ambulatory SBP after 12 weeks. Secondary efficacy endpoints included the change from baseline in mean 24-hour ambulatory SBP; change from baseline in ambulatory BP during the daytime (8:00 am-4:00 pm), nighttime (10:00 pm-6:00 am) and the last 6, 4 and 2 hours of the dosing interval; change from baseline in SeBP at each titration step and at study end; and the proportion of patients achieving mean 24-hour ambulatory BP targets and SeBP goals at week 12. The frequency and severity of treatment-emergent adverse events (TEAEs) were also documented.
RESULTS: Baseline and week 12 ABPM data were available for 150 out of 178patients who entered the active treatment phase. Changes from baseline in mean 24-hour ambulatory BP were -26.0/-12.5 mmHg and -24.9/-12.0 mmHg in patients aged ≥65 to ≤75 years (n = 128) and >75 years (n = 48), respectively (all p < 0.0001 vs baseline). Changes from baseline in mean 24-hour ambulatory BP were -26.0/-13.0 mmHg and -25.4/-11.5 mmHg in male (n = 92) and female (n = 84) patients, respectively (all p < 0.0001 vs baseline) and -26.7/-11.8 mmHg and -25.6/-12.4 mmHg in Black (n = 28) and non-Black (n = 148) patients, respectively (all p < 0.0001 vs baseline). Clinically significant ambulatory BP reductions were observed during the daytime, nighttime and the last 6, 4 and 2 hours of the dosing interval in all subgroups. Changes from baseline at week 12 in mean SeBP were similar to 24-hour ambulatory BP changes reported previously. At week 12, the proportion of patients achieving the 24-hour ambulatory BP target of <130/80 mmHg ranged from 67.5% to 77.4% and achieving the SeBP goal of <140/90 mmHg ranged from 60.7% to 68.8% across the subgroups. Most TEAEs and drug-related TEAEs were mild or moderate in severity, and there were no trends across subgroups.
CONCLUSIONS: In a subgroup analysis based upon age, sex and race in patients aged ≥65 years with hypertension, an OM/HCTZ-based algorithm was efficacious and well tolerated. ClinicalTrials.gov Identifier: NCT00412932.
Authors:
Joel Neutel; Dean J Kereiakes; Kathy A Stoakes; Jen-Fue Maa; Ali Shojaee; William F Waverczak
Related Documents :
21793327 - Effects of one-year swimming training on blood pressure and insulin sensitivity in mild...
22707027 - Comparison of airway control methods and ventilation success with an automatic resuscit...
7498657 - Effect of volume expansion on systemic hemodynamics and central and arterial blood volu...
18334417 - A quantitative method based on total relative change for dynamic electrical impedance t...
2590907 - Mechanism of the apparent parasympathetic inhibition of adenosine induced heart rate sl...
16893747 - Assessing risk and preventing pressure ulcers in patients with cancer.
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Drugs & aging     Volume:  28     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-06-06     Completed Date:  2012-01-26     Revised Date:  2013-08-15    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  477-90     Citation Subset:  IM    
Affiliation:
Orange County Research Center, Tustin, California, USA. jmneutel@aol.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
African Continental Ancestry Group
Age Distribution
Aged
Ambulatory Care
Blood Pressure / drug effects*
Continental Population Groups*
Female
Humans
Hydrochlorothiazide / adverse effects,  pharmacology*
Imidazoles / adverse effects,  pharmacology*
Male
Sex Distribution
Tetrazoles / adverse effects,  pharmacology*
Chemical
Reg. No./Substance:
0/Imidazoles; 0/Tetrazoles; 58-93-5/Hydrochlorothiazide; 6M97XTV3HD/olmesartan medoxomil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High Concomitant Use of Interacting Drugs and Low Use of Gastroprotective Drugs among NSAID Users in...
Next Document:  Risk Factors for Prescribing and Transcribing Medication Errors among Elderly Patients during Acute ...